title: Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
abstract: The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.
authors.affiliation: Department of Hematology, Oncology & Blood & Marrow Transplantation & the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Letendre
authors.affiliation: Department of Hematology, Oncology & Blood & Marrow Transplantation & the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
authors.forename: Varun
authors.initials: V
authors.lastname: Monga
authors.affiliation: Department of Hematology, Oncology & Blood & Marrow Transplantation & the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Milhem
authors.affiliation: Department of Hematology, Oncology & Blood & Marrow Transplantation & the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
authors.forename: Yousef
authors.initials: Y
authors.lastname: Zakharia
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D000074324:Ipilimumab
keywords: CTLA-4 antibody; checkpoint blockade; immunomodulatory; ipilimumab; melanoma; metastatic melanoma